VistaGen Therapeutics, Inc.

VTGN Healthcare Biotechnology

VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.

0.20 0.01 −4.76%
Market cap
$9.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
3/9
Altman Z
−16.79
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

2 3 3 3
ROE
(78.13%) (101.55%) (131.59%) (166.46%)
ROA
(67.86%) (85.21%) (104.86%) (129.22%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(94.57%) (133.57%) (201.55%) (287.83%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.49) (1.43) (1.75) (1.45)
Free Cash Flow
(53.16) (60.54) (66.59) (62.30)
Capital Expenditures
(0.21) (0.24) (0.15) —
Other line items
Cash ROIC
(37.04%) (53.72%) (82.28%) (110.83%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
6,810.68% 6,585.19% 4,332.07% 2,167.21%
Selling, General and Administrative Expense of Revenue
2,370.04% 2,362.66% 1,451.62% 718.47%
Share Based Compensation of Revenue
562.41% 515.32% 314.97% 162.81%
Operating CF/Net income
0.85 0.90 0.95 0.92
Depreciation/Fixed assets
(0.64) (0.74) (0.81) (0.90)
Capex/Depreciation
0.65 0.68 0.44 0.00
Revenue per Share
0.02 0.02 0.03 0.06
Operating CF per Share
(1.48) (1.43) (1.74) (1.45)
Capex per Share
(0.01) (0.01) 0.00 0.00
Capex to Sales
0.30 0.30 0.12 0.00

Fold the line items

Columns are period end dates